Major NHS Study Shows Wearable Device is Effective Treatment for Anxiety

Alpha-Stim AID benefits people with Moderate to Severe Generalised Anxiety Disorder 

(video clip courtesy of SkyNews)

The first clinical results of a major NHS study on how Cranial Electrotherapy Stimulation (CES) provided by the Alpha-Stim AID medical device have been released.

The study, lead by Richard Morriss, Professor of Psychiatry and Community Mental Health at the University of Nottingham, shows that the wearable device can help patients with anxiety disorders.

Conducted under the auspices of The National Institute for Health Research, Professor Moriss and his associate’s research found that 
patients with moderate to severe generalised anxiety disorders, who had already tried basic psychological therapies unsuccessfully, were able to show remarkable improvements in thier condition.

A total of 161 patients took part in the trial, and each patient’s results were measured for 24 weeks. The treatment procedure involved 60-minute self-directed Alpha-Stim AID CES treatment sessions undertaken at the participant’s home, on a daily basis for 6 weeks for all participants. Following 6 weeks of Alpha-Stim AID CES treatment, participants had the option to receive a further 6 weeks of treatment and were then measured at 24 weeks after a minimum period of 12 weeks without treatment to see if the changes seen during the active treatment weeks had been maintained. The study started in October last year with the final patient measurements due to be taken in December of this year.

CES is already widely used in the US, particularly by the American armed forces, to help those suffering with PTSD. The results of Professor Morriss’s trial will hopefully help give many thousand more patients the chance to try this unique drug-free treatment that can be easily and safely used at home.

One in four people in the UK will experience a mental health problem in any given year [2] and the Improving Access to Psychological Therapies programme (IAPT) was introduced by the NHS in 2008 to help facilitate better access to treatment for patients throughout England suffering from anxiety and depression. Over 900,000 patients now use IAPT services each year.

The Alpha-Stim AID device works on the same electrical pathways that naturally occur in the brain and stimulates the nerve cells in the brain stem, the control centre of the brain. 98 percent of the synaptic communication in the brain is electrical rather than chemical and the treatment encourages the production of alpha-waves in the brain. It also stimulates the brain cells to trigger a reaction to produce Serotonin. Anti-depressant drugs (SSRI’s) do the same, but cranial electrotherapy stimulation does this without any lasting side-effects. Its positive effects are also cumulative, suggesting that the Alpha-Stim may bring about a permanent positive change in our neurological make-up.

Explore More:

The Alpha-Stim AID is available from Peak Health Online, your authorised dealer serving the UK & Europe. To explore more, visit our main website here

About study lead, Professor Richard Morriss

Professor Richard Morriss is a Consultant in General Adult and Community Psychiatry with Nottinghamshire Healthcare NHS Trust and Professor of Psychiatry and Community Mental Health at the University of Nottingham. He trained in psychiatry in Leeds, Johns Hopkins Hospital in Baltimore United States, Oxford and Manchester. He has a MD from University of Leeds.

Professor Morriss has clinical interests in mood disorders, somatization and primary care psychiatry. His research interests are in the management of bipolar affective disorder, depression and medically unexplained symptoms in primary and secondary care settings.

He was also a member of the NICE Guideline Development Group (GDG) for Bipolar Disorder and is currently a member of the NICE mental health panel.